Kuczinski Anthony J purchased $105K of RYAN

Kuczinski Anthony J purchased 3,000 shares of RYAN SPECIALTY HOLDINGS, INC. (RYAN) at an average of $34.99 ($34.83–$35.77, $0.10M total) across 2 trades over 2026-06-11 to 2026-06-12.

Original reporting
SEC EDGAR · Kuczinski Anthony J
Published Jun 15, 2026, 8:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 8:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RYAN
Bullish
medium confidence
Mentioned
$RYAN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RYANBullishLow
01

Why it matters

The newest concrete fact is the director’s open-market purchase details (shares, price range, total value) disclosed on 2026-06-15.

02

Market read

Traders may treat the filing as a small sentiment input, but it does not introduce earnings, guidance, or regulatory/contract catalysts.

03

What to watch

No 10b5-1 plan is cited, but the trades were spread across two days and the article provides no context on prior holdings, options, or compensation-driven activity.

Relevance 5/10Novelty 6/10Timing: Filed 2026-06-15; trades occurred 2026-06-11 to 2026-06-12.

Background

The article is an SEC Form 4 insider transaction disclosure for RYAN Specialty Holdings, Inc.

Company-level read

Ticker impact

$RYANBullishMedium confidence
Context

SEC Form 4 shows director Anthony J. Kuczinski bought 3,000 shares of RYAN Specialty Holdings at $34.83–$35.77 (avg $34.99).

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than earnings or guidance-driven.

Evidence & confidence

The filing is a routine Form 4 insider buy with modest size relative to company fundamentals and no accompanying operational or financial disclosure.

Market effects

Minimal; insider buying in a single issuer typically does not reset sector expectations.

None indicated.

None indicated.

Counterpoint

A director buy can be driven by diversification, liquidity planning, or non-informational motives; it may not reflect near-term performance.

Key entities

  • RYAN Specialty Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Anthony J. Kuczinski

    Director who purchased 3,000 shares in open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RYANMed

Ryan Specialty Holdings Inc (RYAN) (Q3 2026) Earnings Call Highlights: Revenue Growth

Ryan Specialty Holdings (RYAN) reported Q3 2026 revenue growth slowing to 4% from 15% YoY, with adjusted EBITDAC margin down 30 bps to 30.9%. The company cited market challenges, including property pricing declines and increased competition. Management expects continued pressure in Q4 2026 and 2027, with modest margin expansion anticipated. They also discussed growth opportunities in reinsurance and AI-related risks, and potential M&A activity in 2027.

Med

Ryan Specialty grows revenue as property softening squeezes E&S returns

Ryan Specialty reported a 4.7% revenue increase to $790M in Q3 2026, driven by casualty lines, while property revenue declined. Underwriting management grew 5.4%, expanding its share of total revenue. Expenses rose 9.9%, outpacing revenue growth. The company maintained its full-year guidance for mid-single-digit organic revenue growth and reported a 3.8% increase in adjusted EBITDAC to $244.4M.